DES MOINES, Iowa, Aug. 2, 2016 /PRNewswire/ -- Eurofins QTA Inc. (US) and Q-Interline A/S (Denmark) are excited to announce a signed collaboration for the North American market. This process will take effect immediately and seeks to strengthen the market offering of both Eurofins QTA and Q-Interline.
Eurofins QTA will provide installation, application support, calibration development and maintenance services for this new technology. North American customers using Q-Interline's FT-IR and FT-NIR instruments, with their patented QTA technology, will experience a more robust and superior performance from NIR analysis.
"We are expecting a lot from entering into this collaboration with Eurofins QTA, since it will give our customers access to highly skilled local support. Eurofins QTA has extensive experience in the field of servicing customers and securing analytical results of very high quality. We are very pleased that Eurofins QTA will be offering our FT-IR and FT-NIR platform for their QTA concept," said Per Sand, Sales Manager of Q-Interline.
With the completion of the Quant driver and its connectivity technology, Q-Interline's Quant FT-IR and FT-NIR analytical solutions can be offered for the Quality Trait Analysis Concept (QTA Concept) of Eurofins. Under the QTA Concept, customers have access to high quality analytical results, without the difficulty of maintaining calibrations. For more information on the QTA concept, please visit http://www.eurofinsus.com/food-testing/laboratories/eurofins-qta/.
"The successful implementation of NIR analysis is dependent upon the integration of high quality instruments and the expertise to create, monitor and optimize operational algorithms for those instruments in day-to-day operations. As the leading players in each of these two areas, the collaboration of Q-interline and QTA bridges the gap between these two areas that, too often, exists for the end user of infrared analysis. Additionally, the reliable wet chemistry data from Eurofins laboratories insures the accurate and precise date that is fundamental to the robust NIR methods that are the mainstay of QTA's business model, " said Dr. Ching-Hui Tseng, Founder and Chief Technical Officer of Eurofins QTA.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.
With 16,000 staff in more than 200 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.